Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
Recent phase III trials have proven the fact that adding bevacizumab to irinotecan plus infusional 5-fluorouracil (5-FU)/leucovorin (LV) should be preferred as a first-line treatment for metastatic colorectal cancer (mCRC). But, since the data regarding bevacizumab administered together with capecit...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2010-09, Vol.27 (3), p.585-591 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 591 |
|---|---|
| container_issue | 3 |
| container_start_page | 585 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 27 |
| creator | Degirmenci, M. Karaca, B. Gorumlu, G. Durusoy, R. Demir Piskin, G. Bozkurt, M. T. Cirak, Y. Tunali, D. Karabulut, B. Sanli, U. A. Uslu, R. |
| description | Recent phase III trials have proven the fact that adding bevacizumab to irinotecan plus infusional 5-fluorouracil (5-FU)/leucovorin (LV) should be preferred as a first-line treatment for metastatic colorectal cancer (mCRC). But, since the data regarding bevacizumab administered together with capecitabin, an oral fluoropyrimidine, and irinotecan in patients with mCRC is limited, we aimed to analyse the efficacy and safety of bevacizumab with capecitabine plus irinotecan (BEV-CAPIRI) regimen in mCRC patients. Records of patients treated with BEV-CAPIRI regimen between January 2005 and March 2008 were reviewed. Efficacy data regarding response rates (RR) as well as safety data were collected. Progression free survival (PFS) and overall survival (OS) analyses were done by using the Kaplan–Meier method. A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen. The median age of this population was 57.3 ± 11.5 (range 29–78). The treatment was well tolerated. The RR was 43.3%, while 30.1% of the patients achieved stable disease (SD). Median PFS and OS were 12.6 ± 1.4 and 20.6 ± 1.7 months, respectively. However, median OS was 21.3 months for male and 14.6 months for female patients. In addition, median OS and PFS was 25.3 months and 16.2 months for the patients who received BEV-CAPIRI as first-line treatment, respectively, and for the other patients it was 15.2 months and 10.2 months, respectively. In conclusion, BEV-CAPIRI is an effective and well-tolerated alternative regimen for mCRC, leading to disease control in a vast majority of patients with mCRC. |
| doi_str_mv | 10.1007/s12032-009-9253-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_872079479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2376357211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-827e761309ec5712101e4e41c7505181c7d5b42a1fc4dd6ace07a93cbfaafd7a3</originalsourceid><addsrcrecordid>eNp1kE1rHDEMhk1JadK0P6CXYHKfVvKM1-tjCUlbWOilhd6MxiMHh_nY2J7C5tfX6S7klJMEet5X8AjxCeEzApgvGRW0qgGwjVW6bfQbcYFa2wZb_HNW91abBvQGzsX7nB8AFGpl34lztFptFOCFGG9DiJ78QdI8yEyBy0EuQfb8l3x8Wifq5X5cs_S0Zx8L9XHm_2xMcV4Ke5pl4vs48SzDkuTEhXKhEr30y7gk9oXGmp49pw_ibaAx88fTvBS_725_3Xxvdj-__bj5umt8a6A0W2XYbLAFy14bVAjIHXfojQaN2zoH3XeKMPhuGDbkGQzZ1veBKAyG2ktxfezdp-Vx5Vzcw7Kmub50W6PA2M7YCuER8mnJOXFw-xQnSgeH4J71uqNeV_W6Z71O18zVqXjtJx5eEiefFVBHINfTfM_p5fPrrf8A--iG4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>872079479</pqid></control><display><type>article</type><title>Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Degirmenci, M. ; Karaca, B. ; Gorumlu, G. ; Durusoy, R. ; Demir Piskin, G. ; Bozkurt, M. T. ; Cirak, Y. ; Tunali, D. ; Karabulut, B. ; Sanli, U. A. ; Uslu, R.</creator><creatorcontrib>Degirmenci, M. ; Karaca, B. ; Gorumlu, G. ; Durusoy, R. ; Demir Piskin, G. ; Bozkurt, M. T. ; Cirak, Y. ; Tunali, D. ; Karabulut, B. ; Sanli, U. A. ; Uslu, R.</creatorcontrib><description>Recent phase III trials have proven the fact that adding bevacizumab to irinotecan plus infusional 5-fluorouracil (5-FU)/leucovorin (LV) should be preferred as a first-line treatment for metastatic colorectal cancer (mCRC). But, since the data regarding bevacizumab administered together with capecitabin, an oral fluoropyrimidine, and irinotecan in patients with mCRC is limited, we aimed to analyse the efficacy and safety of bevacizumab with capecitabine plus irinotecan (BEV-CAPIRI) regimen in mCRC patients. Records of patients treated with BEV-CAPIRI regimen between January 2005 and March 2008 were reviewed. Efficacy data regarding response rates (RR) as well as safety data were collected. Progression free survival (PFS) and overall survival (OS) analyses were done by using the Kaplan–Meier method. A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen. The median age of this population was 57.3 ± 11.5 (range 29–78). The treatment was well tolerated. The RR was 43.3%, while 30.1% of the patients achieved stable disease (SD). Median PFS and OS were 12.6 ± 1.4 and 20.6 ± 1.7 months, respectively. However, median OS was 21.3 months for male and 14.6 months for female patients. In addition, median OS and PFS was 25.3 months and 16.2 months for the patients who received BEV-CAPIRI as first-line treatment, respectively, and for the other patients it was 15.2 months and 10.2 months, respectively. In conclusion, BEV-CAPIRI is an effective and well-tolerated alternative regimen for mCRC, leading to disease control in a vast majority of patients with mCRC.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-009-9253-5</identifier><identifier>PMID: 19526201</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject><![CDATA[Adenocarcinoma - drug therapy ; Adenocarcinoma - secondary ; Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - adverse effects ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Camptothecin - administration & dosage ; Camptothecin - adverse effects ; Camptothecin - analogs & derivatives ; Capecitabine ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - pathology ; Colorectal cancer ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Disease-Free Survival ; Fatigue - chemically induced ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Fluorouracil - analogs & derivatives ; Gastrointestinal Diseases - chemically induced ; Hematologic Diseases - chemically induced ; Hematology ; Humans ; Hypertension - chemically induced ; Internal Medicine ; Kaplan-Meier Estimate ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Proteins - antagonists & inhibitors ; Oncology ; Original Paper ; Pathology ; Rectal Neoplasms - drug therapy ; Rectal Neoplasms - pathology ; Retrospective Studies ; Vascular Endothelial Growth Factor A - antagonists & inhibitors]]></subject><ispartof>Medical oncology (Northwood, London, England), 2010-09, Vol.27 (3), p.585-591</ispartof><rights>Humana Press Inc. 2009</rights><rights>Springer Science+Business Media, LLC 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-827e761309ec5712101e4e41c7505181c7d5b42a1fc4dd6ace07a93cbfaafd7a3</citedby><cites>FETCH-LOGICAL-c370t-827e761309ec5712101e4e41c7505181c7d5b42a1fc4dd6ace07a93cbfaafd7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-009-9253-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-009-9253-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19526201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Degirmenci, M.</creatorcontrib><creatorcontrib>Karaca, B.</creatorcontrib><creatorcontrib>Gorumlu, G.</creatorcontrib><creatorcontrib>Durusoy, R.</creatorcontrib><creatorcontrib>Demir Piskin, G.</creatorcontrib><creatorcontrib>Bozkurt, M. T.</creatorcontrib><creatorcontrib>Cirak, Y.</creatorcontrib><creatorcontrib>Tunali, D.</creatorcontrib><creatorcontrib>Karabulut, B.</creatorcontrib><creatorcontrib>Sanli, U. A.</creatorcontrib><creatorcontrib>Uslu, R.</creatorcontrib><title>Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Recent phase III trials have proven the fact that adding bevacizumab to irinotecan plus infusional 5-fluorouracil (5-FU)/leucovorin (LV) should be preferred as a first-line treatment for metastatic colorectal cancer (mCRC). But, since the data regarding bevacizumab administered together with capecitabin, an oral fluoropyrimidine, and irinotecan in patients with mCRC is limited, we aimed to analyse the efficacy and safety of bevacizumab with capecitabine plus irinotecan (BEV-CAPIRI) regimen in mCRC patients. Records of patients treated with BEV-CAPIRI regimen between January 2005 and March 2008 were reviewed. Efficacy data regarding response rates (RR) as well as safety data were collected. Progression free survival (PFS) and overall survival (OS) analyses were done by using the Kaplan–Meier method. A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen. The median age of this population was 57.3 ± 11.5 (range 29–78). The treatment was well tolerated. The RR was 43.3%, while 30.1% of the patients achieved stable disease (SD). Median PFS and OS were 12.6 ± 1.4 and 20.6 ± 1.7 months, respectively. However, median OS was 21.3 months for male and 14.6 months for female patients. In addition, median OS and PFS was 25.3 months and 16.2 months for the patients who received BEV-CAPIRI as first-line treatment, respectively, and for the other patients it was 15.2 months and 10.2 months, respectively. In conclusion, BEV-CAPIRI is an effective and well-tolerated alternative regimen for mCRC, leading to disease control in a vast majority of patients with mCRC.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - secondary</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - adverse effects</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Capecitabine</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colorectal cancer</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease-Free Survival</subject><subject>Fatigue - chemically induced</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Gastrointestinal Diseases - chemically induced</subject><subject>Hematologic Diseases - chemically induced</subject><subject>Hematology</subject><subject>Humans</subject><subject>Hypertension - chemically induced</subject><subject>Internal Medicine</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - antagonists & inhibitors</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Rectal Neoplasms - pathology</subject><subject>Retrospective Studies</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1rHDEMhk1JadK0P6CXYHKfVvKM1-tjCUlbWOilhd6MxiMHh_nY2J7C5tfX6S7klJMEet5X8AjxCeEzApgvGRW0qgGwjVW6bfQbcYFa2wZb_HNW91abBvQGzsX7nB8AFGpl34lztFptFOCFGG9DiJ78QdI8yEyBy0EuQfb8l3x8Wifq5X5cs_S0Zx8L9XHm_2xMcV4Ke5pl4vs48SzDkuTEhXKhEr30y7gk9oXGmp49pw_ibaAx88fTvBS_725_3Xxvdj-__bj5umt8a6A0W2XYbLAFy14bVAjIHXfojQaN2zoH3XeKMPhuGDbkGQzZ1veBKAyG2ktxfezdp-Vx5Vzcw7Kmub50W6PA2M7YCuER8mnJOXFw-xQnSgeH4J71uqNeV_W6Z71O18zVqXjtJx5eEiefFVBHINfTfM_p5fPrrf8A--iG4Q</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Degirmenci, M.</creator><creator>Karaca, B.</creator><creator>Gorumlu, G.</creator><creator>Durusoy, R.</creator><creator>Demir Piskin, G.</creator><creator>Bozkurt, M. T.</creator><creator>Cirak, Y.</creator><creator>Tunali, D.</creator><creator>Karabulut, B.</creator><creator>Sanli, U. A.</creator><creator>Uslu, R.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20100901</creationdate><title>Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer</title><author>Degirmenci, M. ; Karaca, B. ; Gorumlu, G. ; Durusoy, R. ; Demir Piskin, G. ; Bozkurt, M. T. ; Cirak, Y. ; Tunali, D. ; Karabulut, B. ; Sanli, U. A. ; Uslu, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-827e761309ec5712101e4e41c7505181c7d5b42a1fc4dd6ace07a93cbfaafd7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - secondary</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - adverse effects</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Capecitabine</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colorectal cancer</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease-Free Survival</topic><topic>Fatigue - chemically induced</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Gastrointestinal Diseases - chemically induced</topic><topic>Hematologic Diseases - chemically induced</topic><topic>Hematology</topic><topic>Humans</topic><topic>Hypertension - chemically induced</topic><topic>Internal Medicine</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - antagonists & inhibitors</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Rectal Neoplasms - pathology</topic><topic>Retrospective Studies</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Degirmenci, M.</creatorcontrib><creatorcontrib>Karaca, B.</creatorcontrib><creatorcontrib>Gorumlu, G.</creatorcontrib><creatorcontrib>Durusoy, R.</creatorcontrib><creatorcontrib>Demir Piskin, G.</creatorcontrib><creatorcontrib>Bozkurt, M. T.</creatorcontrib><creatorcontrib>Cirak, Y.</creatorcontrib><creatorcontrib>Tunali, D.</creatorcontrib><creatorcontrib>Karabulut, B.</creatorcontrib><creatorcontrib>Sanli, U. A.</creatorcontrib><creatorcontrib>Uslu, R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Degirmenci, M.</au><au>Karaca, B.</au><au>Gorumlu, G.</au><au>Durusoy, R.</au><au>Demir Piskin, G.</au><au>Bozkurt, M. T.</au><au>Cirak, Y.</au><au>Tunali, D.</au><au>Karabulut, B.</au><au>Sanli, U. A.</au><au>Uslu, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>27</volume><issue>3</issue><spage>585</spage><epage>591</epage><pages>585-591</pages><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Recent phase III trials have proven the fact that adding bevacizumab to irinotecan plus infusional 5-fluorouracil (5-FU)/leucovorin (LV) should be preferred as a first-line treatment for metastatic colorectal cancer (mCRC). But, since the data regarding bevacizumab administered together with capecitabin, an oral fluoropyrimidine, and irinotecan in patients with mCRC is limited, we aimed to analyse the efficacy and safety of bevacizumab with capecitabine plus irinotecan (BEV-CAPIRI) regimen in mCRC patients. Records of patients treated with BEV-CAPIRI regimen between January 2005 and March 2008 were reviewed. Efficacy data regarding response rates (RR) as well as safety data were collected. Progression free survival (PFS) and overall survival (OS) analyses were done by using the Kaplan–Meier method. A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen. The median age of this population was 57.3 ± 11.5 (range 29–78). The treatment was well tolerated. The RR was 43.3%, while 30.1% of the patients achieved stable disease (SD). Median PFS and OS were 12.6 ± 1.4 and 20.6 ± 1.7 months, respectively. However, median OS was 21.3 months for male and 14.6 months for female patients. In addition, median OS and PFS was 25.3 months and 16.2 months for the patients who received BEV-CAPIRI as first-line treatment, respectively, and for the other patients it was 15.2 months and 10.2 months, respectively. In conclusion, BEV-CAPIRI is an effective and well-tolerated alternative regimen for mCRC, leading to disease control in a vast majority of patients with mCRC.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>19526201</pmid><doi>10.1007/s12032-009-9253-5</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2010-09, Vol.27 (3), p.585-591 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_journals_872079479 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - secondary Adult Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Capecitabine Colonic Neoplasms - drug therapy Colonic Neoplasms - pathology Colorectal cancer Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Disease-Free Survival Fatigue - chemically induced Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - analogs & derivatives Gastrointestinal Diseases - chemically induced Hematologic Diseases - chemically induced Hematology Humans Hypertension - chemically induced Internal Medicine Kaplan-Meier Estimate Male Medicine Medicine & Public Health Middle Aged Neoplasm Proteins - antagonists & inhibitors Oncology Original Paper Pathology Rectal Neoplasms - drug therapy Rectal Neoplasms - pathology Retrospective Studies Vascular Endothelial Growth Factor A - antagonists & inhibitors |
| title | Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A25%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20bevacizumab%20plus%20capecitabine%20and%20irinotecan%20regimen%20for%20metastatic%20colorectal%20cancer&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Degirmenci,%20M.&rft.date=2010-09-01&rft.volume=27&rft.issue=3&rft.spage=585&rft.epage=591&rft.pages=585-591&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-009-9253-5&rft_dat=%3Cproquest_cross%3E2376357211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=872079479&rft_id=info:pmid/19526201&rfr_iscdi=true |